Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination

Virology

Volumn 294, Issue 1, 2002, Pages 47-59

  Michel, Nico ^a   Osen, Wolfram ^a   Gissmann, Lutz ^a   Schumacher, Ton N M ^b   Zentgraf, Hanswalter ^a   Müller, Martin ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HERPES SIMPLEX VIRUS FERRY PROTEIN; HYBRID PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; FEMALE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; VACCINATION; VIRUS GENE; WART VIRUS;

HUMAN PAPILLOMAVIRUS TYPE 16; SIMPLEXVIRUS;

EID: 0036065502     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2001.1321     Document Type: Article

References (49)

1. E7-specific cytotoxic T cell tolerance in HPV-transgenic mice
2. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
3. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
4. Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif
5. Preventing cervical cancer
6. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7
7. Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment
8. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein VP22
9. Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization
10. DNA vaccination as an approach to malaria control: Current status and strategies
11. Intercellular trafficking and protein delivery by a herpesvirus structural protein
12. The herpes simplex virus type 1 tegument protein VP22 is encoded by gene UL49
13. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
14. Potential strategies utilised by papillomavirus to evade host immunity
15. Human papillomaviruses and genital cancer
16. Therapeutic vaccines for human papillomaviruses
17. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model
18. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16
19. Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen
20. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors
21. Virus-specific basic phosphoproteins associated with herpes simplex virus type a (HSV-1) particles and the chromatin of HSV-1-infected cells
22. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides
23. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
24. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer
25. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism
26. Monoclonal antibodies specific for the carboxy terminus of simian virus 40 large T antigen
27. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive
28. Chimeric papillomavirus-like particles
29. Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens
30. A genetic immunization adjuvant system based on BVP22-antigen fusion
31. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity
32. Intercellular delivery of functional p53 by the herpesvirus protein VP22
33. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2
34. DNA immunization: Ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction
35. Genetic engineering of proteins with cell membrane permeability
36. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection
37. Papillomavirus-like particle vaccines
38. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells
39. Human papillomavirus type 16 E7 DNA vaccine: Mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity
40. DNA vaccine against oncogenic hamster cells transformed by HPV16 E6/E7 oncogenes and the activated ras oncogene
41. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: Conditions, efficiency, and relation to antibody responses
42. Immunomanipulative strategies for the control of human papillomavirus associated cervical disease
43. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans
44. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results
45. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells
46. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity
47. DNA immunization: Mechanistic studies
48. Targeting dendritic cells to enhance DNA vaccine potency
49. Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis